FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Neal James R
2. Issuer Name and Ticker or Trading Symbol

XOMA Corp [ XOMA ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CEO
(Last)          (First)          (Middle)

C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310
3. Date of Earliest Transaction (MM/DD/YYYY)

11/6/2019
(Street)

EMERYVILLE, CA 94608
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  11/6/2019    M    4348  A $5.50  22017  D   
Common Stock  11/6/2019    S(1)    4348  D $22.00  17669  D   
Common Stock                 4202  I  by 401(k) 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $5.50  11/6/2019    M        4348   12/21/2017  12/22/2026  Common Stock  4348  $0  56000  D   

Explanation of Responses:
(1)  The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Neal James R
C/O XOMA CORPORATION
2200 POWELL STREET, SUITE 310
EMERYVILLE, CA 94608
X
CEO

Signatures
/s/ Thomas Burns, as attorney-in-fact for James R. Neal 11/8/2019
**Signature of Reporting Person Date


Grafico Azioni XOMA (NASDAQ:XOMA)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di XOMA
Grafico Azioni XOMA (NASDAQ:XOMA)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di XOMA

Notizie Xoma Corp - XOMA

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
XOMA Corporation Announces Closing of Tender Offer
Mercoledì 3 Aprile 2024 (2 settimane fa) • GlobeNewswire Inc.
XOMA Declares Quarterly Preferred Stock Dividends
Giovedì 21 Marzo 2024 (4 settimane fa) • GlobeNewswire Inc.
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
Martedì 19 Marzo 2024 (1 mese fa) • GlobeNewswire Inc.
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
Venerdì 8 Marzo 2024 (1 mese fa) • GlobeNewswire Inc.
XOMA to Present at Upcoming Investor Conferences in March
Mercoledì 28 Febbraio 2024 (2 mesi fa) • GlobeNewswire Inc.
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
Venerdì 16 Febbraio 2024 (2 mesi fa) • GlobeNewswire Inc.
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
Giovedì 18 Gennaio 2024 (3 mesi fa) • GlobeNewswire Inc.
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol
Giovedì 11 Gennaio 2024 (3 mesi fa) • Dow Jones News
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
Giovedì 11 Gennaio 2024 (3 mesi fa) • GlobeNewswire Inc.
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
Lunedì 8 Gennaio 2024 (3 mesi fa) • GlobeNewswire Inc.
XOMA Announces Stock Repurchase Program of up to $50 Million
Martedì 2 Gennaio 2024 (4 mesi fa) • GlobeNewswire Inc.
XOMA Declares Quarterly Preferred Stock Dividends
Mercoledì 20 Dicembre 2023 (4 mesi fa) • GlobeNewswire Inc.